3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More

Laboratory Test Tubes

The biotech industry saw solid growth last year driven by the demand for therapies to combat COVID-19. But advances in technology helped biotech companies deliver impressive drug candidates for treating other serious ailments too. Consequently, Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more than 45% in the near term. So, let’s evaluate these companies more closely.

With more than 50% of the U.S. population now fully vaccinated for COVID-19 (according to the CDC), biotech companies have shifted their focus to research and development projects for other critical ailments. As a result, the global biotechnology market is expected to grow at a 15.8% CAGR over the next seven years to hit a $2.44 trillion market size by 2028.

Promising clinical trials have fostered increased investor optimism about the industry, as evidenced by the Invesco Dynamic Biotech & Genome ETF’s (PBE) 25.7% returns compared S&P SPDR 500 Trust Fund ETF’s (SPY) 20.4% gains over the past nine months.

Thus, Wall Street analysts believe Organogenesis Holdings Inc., BioDelivery Sciences International, Inc. and Champions Oncology, Inc. have the potential to rally by more than 45% over the next 12 months.

Click here to checkout our Healthcare Sector Report for 2021

Organogenesis Holdings Inc.

ORGO is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care, surgical, and sports medicine markets in the United States. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physicians’ offices through a direct sales force and independent agencies.

On January 14, ORGO enrolled its first patient in its pivotal Phase 3 clinical trial to  evaluate the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with knee osteoarthritis (OA). The company is looking forward to leveraging its Regenerative Medicine Advanced Therapy (RMAT) designation to work closely with the Food and Drug Association (FDA) to expedite ReNu’s review.

1 2 3 4
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.